New Manufacturing Method Improves Drug Delivery of Asthma Inhalers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

New Manufacturing Method Improves Drug Delivery of Asthma Inhalers


A chemical engineering team from Monash University in Australia developed a method to manufacture ultrafine particles that will improve the consistency and efficiency of drugs used in metered-dose inhalers to treat asthma, the University announced in a press release. The anti-solvent vapor precipitation method uses ethanol to dehydrate droplets, which results in ultrafine particles with a more uniform size.

 “Ultrafine uniform particles will ensure that fewer drug particles get stuck in the throat while more can reach the lower regions of the lungs,” said team leader Dr. Meng Wai Woo. “Because we can now make the small particles more uniform, it means the inhalers will work better. From a drug manufacturer’s perspective, this new approach can maintain the uniformity of the particle and yet potentially maintain commercially viable production rates.”

The team’s work results in particles smaller than a micron in diameter. These particles are much smaller than those produced by conventional dehydrating mechanisms, which are limited by the size of the atomized droplet.

Assisted by a grant from the Australian Research Council, the Monash team is now testing its method on whey to research the ultrafine particle delivery of protein-based medicines. The team is also building a demonstration unit, which will be completed later this year, to showcase the anti-solvent vapor precipitation process.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here